Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Equillium, Inc. (EQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program"
05/11/2023 8-K Quarterly results
Docs: "Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates $62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year, and steroid tapering of 99% at Day 169&#x200b"
03/23/2023 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates"
11/14/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates Announced positive topline data from EQUATE study of itolizumab in first-line aGVHD Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Presented interim safety data and reduction in proteinuria from the EQUALISE study of itolizumab in lupus patients Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform"
11/10/2021 8-K Quarterly results
Docs: "Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab Reported interim safety data from first cohort of asthma patients in Phase 1b EQUIP study Company reaffirms guidance for EQUIP Phase 1b topline data in Q4 2021, and updates guidance to commence acute GVHD pivotal study in early 2022 and for interim data from EQUALISE Phase 1b Type B lupus nephritis patients to mid-2022"
03/24/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Equillium Reports Third Quarter 2020 Financial Results and Business Highlights LA JOLLA, Calif., Nov 10, 2020 — Equillium, Inc. , a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020. “We continue to make significant progress towards our goal of bringing itolizumab to patients suffering from a range of severe immuno-inflammatory disorders,” said Bruce Steel, chief executive officer of Equillium. “We are well positioned to continue advancing our core trials including the Phase 1b EQUATE trial in acute graft-versus-host disease where we recently reported positive response rates across the first three dose cohorts, as well as our Phase 1b EQUIP and EQUALISE trials in unc..."
08/12/2020 8-K Quarterly results
05/13/2020 8-K Quarterly results
Docs: "Equillium Reports First Quarter 2020 Financial Results"
03/26/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
Docs: "Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights",
"Equillium Announces Leadership Updates Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and Dan Bradbury will remain on the Board of Directors as Executive Chairman."
08/12/2019 8-K Quarterly results
05/13/2019 8-K Quarterly results
Docs: "Equillium Reports First Quarter 2019 Financial Results and Recent Highlights EQUATE Phase 1b/2 trial in acute graft-versus-host disease ongoing with data expected in 1Q 2020"
03/27/2019 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights Initiated the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in March 2019"
11/15/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report November 15, 2018 Equillium, Inc. Delaware 001-38692 20-3828755 2223 Avenida de la Playa, Suite 108 La Jolla, CA 92037 Registrant's telephone number, including area code: 412-5302 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement c...",
"Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy